Skip to content
← Full study record

NCT01248949 · MORE INFO

Limitations, agreements, and source contact

A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors · Source last updated 2017-03-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
"MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome" in the agreement description.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
information.center@astrazeneca.com
organization
MedImmune, LLC
phone
301-398-0000
title
Mohammed Dar, MD
Complete source fields
certain Agreement
other Details
"MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome" in the agreement description.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
information.center@astrazeneca.com
organization
MedImmune, LLC
phone
301-398-0000
title
Mohammed Dar, MD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice